![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 16, 2020 11:30:24 AM
What I dont get is why they wont attempt to finish the IV Clinical Trial. Just "OK got some good data on 102, we've done enough, dont need 150, in their opinion".
Are they going to settle for EUA only. Its a "safety/ futility review with a "go ahead with more Trial till finished/ stop for S or F / Enough data on you unfinished Phase 2b-no Phase 3 needed". They should have finished recruiting and finished the Trial, IMO. I dont like Their going all in with an unfinished Trial, JMHFO...
Hope their new CRO guy gets patients enrolled to finish that Trial and does better with the Inhaler. Sure Phase 2b Placebo Trials are tough, but not finishing this Trial? Maybe they'll at least get the EUA, BUT???
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM